CD80 and neoplasm: The expression of antigen-presenting biomarker (MHCII+, CD86+, CD80+) on macrophages and DCs was significantly enhanced in tumors treated with CAR-Ms, compared to the Con-Ms group tumor (Fig. 4E, F, Fig. S3B, C), indicating enhanced maturation and antigen-presenting function.